Phenylhydrazine administered to rats at a dose of 4mg/100g body weight per day for 3days, diminished the total ascorbic acid level in liver, kidney and spleen tissues. The total ascorbic acid level in blood was, however, elevated after phenylhydrazine treatment. The other effects of phenylhydrazine treatment were a reduction in the activities of D -glucuronoreductase, L-gulonooxidase, dehydroascorbatase and urono lactonase in liver. The dehydroascorbatase activity in kidney was also diminished after phenylhydrazine treatment. The changes in the activities of liver enzymes were found to be accompanied by a diminution in the level of reduced ascorbic acid and an elevation in the dehydroascorbic acid level. It was concluded that the biosynthesis of L-ascorbic acid from both D -glucuronolactone and L-gulonolactone as substrates, was reduced in phenylhydrazine-treated rats. The degradation of L-ascorbic acid by both liver and kidney was diminished by the phenylhydrazine treatment. It was further concluded that phenylhydrazine-treated rats tried to conserve the level of substrate for the synthesis of L-ascorbic acid, by reducing the hydrolytic cleavage of D-glucuronolactone. The elevated blood ascorbic acid level under the same condition was ascribed to the diminished catabolism of L-ascorbic acid.
Summary
Phenylhydrazine administered to rats at a dose of 4mg/100g body weight per day for 3days, diminished the total ascorbic acid level in liver, kidney and spleen tissues. The total ascorbic acid level in blood was, however, elevated after phenylhydrazine treatment. The other effects of phenylhydrazine treatment were a reduction in the activities of D -glucuronoreductase, L-gulonooxidase, dehydroascorbatase and urono lactonase in liver. The dehydroascorbatase activity in kidney was also diminished after phenylhydrazine treatment. The changes in the activities of liver enzymes were found to be accompanied by a diminution in the level of reduced ascorbic acid and an elevation in the dehydroascorbic acid level. It was concluded that the biosynthesis of L-ascorbic acid from both D -glucuronolactone and L-gulonolactone as substrates, was reduced in phenylhydrazine-treated rats. The degradation of L-ascorbic acid by both liver and kidney was diminished by the phenylhydrazine treatment. It was further concluded that phenylhydrazine-treated rats tried to conserve the level of substrate for the synthesis of L-ascorbic acid, by reducing the hydrolytic cleavage of D-glucuronolactone. The elevated blood ascorbic acid level under the same condition was ascribed to the diminished catabolism of L-ascorbic acid.
Various drugs, including a variety of foreign compounds, influence the metabolism of ascorbic acid (1) (2) (3) (4) (5) (6) (7) (8) . Recently, the effects of hydrazine on ascorbic acid metabolism were demonstrated (9) . The biosynthesis as well as the degradation of L ascorbic acid was found to be affected by the hydrazine treatment. Phenylhydrazine, which is an aromatic hydrazine, is known to cause a hemolytic anemia (10) (11) (12) (13) . Ascorbic acid administration, on the other hand, was reported to cause a marked improvement in anemia induced by phenylhydrazine (14) , while pernicious anemia was found to be accompanied by a reduction in plasma ascorbic acid level (15) . It appears, therefore, phenylhydrazine may have an impact on the metabolism of ascorbic acid and, accordingly, the present investigation was intended to study the effects of phenylhydrazine in vivo on the metabolism of ascorbic acid. 
RESULTS

AND DISCUSSION
The average body weight of phenylhydrazine-treated rats was not found to be different from that of pair-fed control rats (Table 1 ) . This suggests that phenyl hydrazine has no direct effect on the body weight of animals . The weights of liver , kid neys, spleen and adrenals per 100g body weight were , however, increased after phenylhydrazine treatment (Table 1) . Among the organs spleen showed, as expected , maximum enlargement. The weight of the testes per 100g body weight was , however, not altered by the phenylhydrazine treatment . It is known that phenylhydrazine when administered to animals including lower forms of animals caused hemolysis with increasing breakdown of erythrocytes (24) (25) (26) (27) . It was also recognized that the hemolytic activity of phenylhydrazine was accompanied by splenic erythrophago cytosis resulting in increased spleen size (24 , 25) . In the present investigation, therefore, the marked increase in spleen size was an effect of hemolytic action of phenylhydrazine. It was suggested that the increased size of the organs (liver, kidney etc.) caused by hydrazine treatment might arise from accumulation of fat (28 , 29) . It is, therefore, possible that the enlargement of other organs (liver , kidney etc.) in phenylhydrazine-treated rats might be the result of accumulation of fat . The results presented in Table 2 reveal that phenylhydrazine treatment reduced the total ascorbic acid levels of liver , kidney and spleen. The fall in total ascorbic acid level in the liver of phenylhydrazine-treated rats was accompanied by reduced activities of both D-glucuronoreductase and L-gulonooxidase (Table 3) . This indicates that the fall in total ascorbic acid level in the liver of phenylhydrazine treated rats resulted from diminished synthesis of L-ascorbic acid . It appears that 216 K. SENGUPTA and A. K. CHATTERJEE Table  1 phenylhydrazine treatment reduced the synthesis of L-ascorbic acid from both D -glucuronolactone and L-gulonolactone as substrates. That phenylhydrazine treat ment causes reduced synthesis of L-ascorbic acid seemed also evident from the diminished level of reduced ascorbic acid in the liver (Table 4 ). The dehy droascorbatase activity of both liver and kidney was depressed by the phenyl hydrazine treatment (Table 5 ). This demonstrates that the conversion of dehy droascorbic acid to 2,3-dioxogulonic acid was reduced after phenylhydrazine treatment. The elevated level of dehydroascorbic acid in the liver of phenylhydrazine treated rats (Table 4 ) also suggests a diminished conversion of dehydroascorbic acid to 2,3-dioxogulonic acid. Inspite of diminished degradation of L-ascorbic acid, the lowering of total ascorbic acid level in the liver of phenylhydrazine-treated rats could be ascribed to the fact that the biosynthesis of L-ascorbic acid was adversely affected since the activities of both the enzymes involved in the biosynthesis of L-ascorbic acid were retarded. Phenylhydrazine treatment also reduced the activity of uronolac tonase in liver (Table 6) , suggesting a diminished hydrolysis of D-glucuronolactone. These studies indicate, therefore, that phenylhydrazine-treated rats showed a tendency to adapt to the altered situation by reducing the hydrolysis of D- glucuronolactone, in an attempt to raise the level of the endogenous substrate for the synthesis of L-ascorbic acid, and also by bringing in a mechanism which caused a diminution in the breakdown of L-ascorbic acid. Although the synthesis of L-ascorbic acid by the liver was diminished, the total ascorbic acid level of whole blood was elevated by the phenylhydrazine treatment (Table 2 ). This elevation in blood ascorbic acid level might arise from the diminished degradation of L-ascorbic acid. In the face of elevated blood ascorbic acid level and diminished degradation of L-ascorbic acid, the fall in total ascorbic acid level in kidney and spleen might be ascribed to the enlargement of the organs or the diminished uptake of ascorbic acid by the tissues from the blood.
Thus, the present studies demonstrate that rats respond to phenylhydrazine treatment by showing a variety of changes in ascorbic acid metabolism.
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